Kaposi sarcoma associated with rituximab-based cytotoxic therapy

Alkan, Ali; Yaşar, Arzu; Toprak, Serhat

doi:10.1177/1078155219835592

Cited by 5 publications

(7 citation statements)

References 15 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab is a human/mouse chimeric monoclonal antibody (IgG1) that targets the CD20 antigen expressed in more than 95% of normal and malignant B cells and induces complement-mediated and antibody-dependent cellular cytotoxicity. It has been reported as a triggering factor for KS [ 26 ]. Rituximab depletes B cells and causes a decrease in T-cell activation because of decreased antigen presentation by B cells.…”

Section: Reviewmentioning

confidence: 99%

Rituximab-Induced Kaposi Sarcoma in HIV-Negative Patients: A Narrative Review

Oprita,

Cotan,

Celmare

et al. 2023

Cureus

View full text Add to dashboard Cite

Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disorder that requires infection with human herpes virus 8 (HHV-8) for it to develop. It is commonly seen in HIV-positive patients and rarely in immunosuppressed HIV-negative patients. Rituximab is a monoclonal anti-CD20 chimeric murine/human immunoglobulin G antibody used to treat B cell lymphoproliferative diseases as well as a variety of autoimmune disorders. Several cases of iatrogenic Kaposi sarcoma (iKS) have been described after rituximab treatment.The purpose of this narrative review is to identify the presence of common clinical characteristics among rituximab-induced KS patients that could facilitate better management of this rare condition.

show abstract

Section: Reviewmentioning

confidence: 99%

Rituximab-Induced Kaposi Sarcoma in HIV-Negative Patients: A Narrative Review

Oprita,

Cotan,

Celmare

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…In all the previous reported cases, rituximab was administered along with other immunosuppressive agents which makes it difficult to delineate its exact role in the development of Kaposi's sarcoma. 7,8 Corticosteroids have also been implicated in the development and the dissemination of Kaposi's sarcoma. 10 Consequently, the role of corticosteroids in the causation of Kaposi's sarcoma in our case cannot be excluded.…”

Section: Sirmentioning

confidence: 99%

Iatrogenic Kaposi’s sarcoma induced by rituximab and corticosteroid treatment for pemphigus vegetans in an HIV-negative patient

Daflaoui

Saddouk

Ouadi

et al. 2022

IJDVL

View full text Add to dashboard Cite

“…42 Integrated approaches combining RTX and chemotherapy are currently favored in MCD management, as they limit KS flaring. 36,43,44 RTX employment for indications other than MCD, such as diffuse large B-cell lymphoma, 45,46 also led to KS development in some case reports.…”

Section: Rituximabmentioning

confidence: 99%

“…A median time to KS diagnosis of 16 weeks was recorded across published cases, ranging from as early as 1-2 weeks to 13 months (Table 4). 37,39,40,41,43,[45][46][47][48][49][50][51][52][53]…”

Section: Rituximabmentioning

confidence: 99%

Kaposi's sarcoma, biologics and small molecules: Navigating the complex interplay between host immunity and viral biology. A case series with focused review of the literature

Brambilla

Maronese

Zelin

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

The consequences of cytokine-specific immune modulation in the development and course of Kaposi's sarcoma (KS) are poorly understood. A retrospective chart review of patients treated with biologic/small molecule drugs and followed at the dedicated KS outpatient service of our Dermatology Unit was performed. The literature on biologic and small molecule drug use in KS patients was also reviewed. Data concerning 12 KS patients treated with biologic/small molecule drugs were collected. After a median delay of 6 months following biologic or small molecule drug introduction, nine patients experienced either KS onset or reactivation. Drugs associated with KS onset or flaring were: rituximab, infliximab, ruxolitinib apremilast (1), mirikizumab, abatacept (1). After a median follow-up of 25 months, all cases achieved persistent complete response through culprit drug discontinuation or drug withdrawal plus treatment. No effect on KS course was recorded with tocilizumab and vedolizumab.Based on our experience with the largest case series reported to date as well as the available literature, tocilizumab and ustekinumab seem to exert an overall neutral effect on KS. On the other hand, rituximab, infliximab, and ruxolitinib have been associated with the development or worsening of pre-existing KS and should be carefully pondered before use. Due to limited and partly controversial evidence, no definitive conclusions can be drawn on vedolizumab, apremilast, mirikizumab, abatacept.

show abstract

Kaposi sarcoma associated with rituximab-based cytotoxic therapy

Cited by 5 publications

References 15 publications

Rituximab-Induced Kaposi Sarcoma in HIV-Negative Patients: A Narrative Review

Rituximab-Induced Kaposi Sarcoma in HIV-Negative Patients: A Narrative Review

Iatrogenic Kaposi’s sarcoma induced by rituximab and corticosteroid treatment for pemphigus vegetans in an HIV-negative patient

Kaposi's sarcoma, biologics and small molecules: Navigating the complex interplay between host immunity and viral biology. A case series with focused review of the literature

Contact Info

Product

Resources

About